宫颈癌疫苗用于18～25岁中国女性预防宫颈癌的药物经济学评价

Economic evaluation of human papillomavirus vaccine versus Chinese women aged 18 to 25 for treating cervical cancer

目的评价人乳头瘤病毒(HPV)疫苗预防宫颈癌的经济有效性。方法构建Markov模型,对中国18~25岁健康女性注射HPV疫苗的长期成本和健康产出进行计算,结合意愿支付水平判断其是否有经济性。通过对成本、贴现率、有效率等指标进行敏感性分析,判断结果是否有一定的敏感性。结果疫苗组成本低、效用高,属于绝对优势方案,其增量成本效用比为43 489/QALY,疫苗组相对于对照组的增量成本效用比小于经济有效性的临界标准,证明疫苗的注射使用是一项经济有效的技术方案。结论 Markov模型表明在18~25岁中国女性中注射HPV疫苗对预防宫颈癌具有较好的经济性。考虑到本研究数据来源、以及模型假设等因素尚存在一定局限性,应积极开展相关临床试验,进行深入研究。

Objective To evaluate the cost effectiveness of human papillomavirus vaccine （HPV） for treating cervical cancer. Methods We constructed a Markov model to evaluate the cost-effectiveness of HPV versus Chinese healthy women aged 18 to 25 for treating Cervical Cancer. We calculated the clinical benefits and cost-effectiveness and judged the results based on willing to pay. Sensitivity analysis was made for parameters like cost, discounting rate and vaccine efficacy. Results HPV vaccination was a cost-effective option under the local willing to pay value with the incremental cost utility ratio 43 489 per QALY gained. It proved that vaccination was an economic and effective solution. Conclusion Given the results of Markov model, the cost effectiveness of HPV vaccination of Chinese women aged 18 to 25 is positive. Considering the data sources and model hypothesis, this report has some limitations. Further studies are warranted.